VK2735 Dosage, half-life & reference guide

Also known as VK-2735 · VK 2735

Reviewed 1 studyEvidence: ModeratePublished by PepVault

A weekly GLP-1 and GIP dual agonist from Viking Therapeutics, the same two-receptor approach as tirzepatide, also being tested as a daily tablet. In its 13-week phase 2 trial, people lost about 9% to 15% of their body weight depending on the dose, with no sign of levelling off.

Studied range
2.5–17.5 mgstarting dose 2.5 mg
How often
Weekly
Half-life
~9 days
Evidence
●●● Moderate
Route
SubQ injection

Studied in research — not a recommendation.

VK2735 dose guide

How it works.

Once-weekly peptide that switches on both the GLP-1 and the GIP receptors, the same pair tirzepatide works through. A side chain stretches its half-life to about 7 to 10 days in people, long enough for weekly shots. The idea is the one tirzepatide proved: two incretin signals that curb appetite and food intake together. Viking also makes it as a daily tablet, the same molecule by mouth. Investigational, in phase 3 since June 2025.

Commonly reported: In trials, nausea and other GI effects early on, fading as the dose holds. It is in phase 3 and not approved anywhere.

Half-life & active level

The half-life of VK2735 is ~9 days (measured in people: 170–250 hours after single doses, Viking phase 1, 2023).

Here's how a typical VK2735 schedule accumulates over four weeks (one-compartment estimate).

An estimate from the half-life above, not a measurement. See your own curve build live in the half-life calculator.

A smiling woman in a dark training top in her kitchen, holding a glass of water

Model. Individual results vary.

PepVault for iPhone

Track VK2735 in PepVault

Log each dose, see how many doses are left in the vial, and keep your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Where VK2735 works.

A body with Appetite & metabolism lit
  • Appetite & metabolism

    In people. In its 13-week phase 2 trial, people lost about 9% to 15% of their body weight depending on the dose, with no sign of levelling off.

An area lights for what a peptide is used for and what people report, with the evidence beside it. It isn’t a promise that it works there.

Week by week.

What to expect in the first 8 weeks

Onset
Days–2 weeks
Peak effect
78 weeks (phase 3 endpoint, not yet read out)
Duration
Ongoing
  1. Day 1–21 · 2.5 mgRCT

    Low start, first weeks

    You're on 2.5 mg, where most of the phase 2 trial began. Commonly reported: appetite dropping within days. In that trial, GI side effects came early and faded, and the group that skipped this start had the worst first-week nausea.

    The science

    VENTURE (Bays 2026, Obesity; 176 adults without diabetes): all groups started at 2.5 mg except the 15 mg group, which started at 5.0 mg; nausea was highest in that group's first week, and GI AEs "were generally observed early in the study and subsided over time". The authors: "The clear benefit of starting below 5.0 mg and titrating up has informed the phase 3 trial design".

    Sources
    • Bays et al. (VENTURE) (2026)

    Updated Nov 2026

  2. Day 22–91RCT

    The first 13 weeks

    In the phase 2 trial, every dose took off weight quickly: about 9% on the lowest and 15% on the highest by week 13, against about 2% on placebo. Nearly everyone on the drug lost at least 5%.

    The science

    VENTURE week 13 (mITT, MMRM): 2.5 mg −9.1%, 5 mg −10.9%, 10 mg −12.9%, 15 mg −14.7% vs −1.7% on placebo (all p < 0.0001); 9.2 to 14.6 kg; 93% (130/140) reached at least 5% loss vs 12% (4/34) on placebo (Bays 2026). Viking reported no sign of a plateau at week 13.

    Sources
    • Bays et al. (VENTURE) (2026)

    Updated Nov 2026

  3. Day 22–546 · 7.5 mgRCT

    The lowest phase 3 dose

    You're at 7.5 mg, the lowest of the three doses in the phase 3 trials. In phase 2, doses around here took off about 11% to 13% in 13 weeks. Commonly reported: appetite control holding, with GI effects quieter once the dose stays put.

    The science

    VANQUISH-1 and -2 randomize to 7.5, 12.5 or 17.5 mg weekly or placebo for 78 weeks (Viking, Oct-28-2026; NCT07104500, NCT07104383). VENTURE's neighbouring doses: 5 mg −10.9% and 10 mg −12.9% at week 13 (Bays 2026). Phase 3 results are expected after its primary completion (estimated Jul-2027).

    Sources
    • Bays et al. (VENTURE) (2026)
    • Viking (Q3 2026 update) (2026)

    Updated Nov 2026

  4. Day 43–546 · 12.5 mgRCT

    The middle phase 3 dose

    You're at 12.5 mg, the middle phase 3 dose. In phase 2, 10 mg and 15 mg took off about 13% and 15% in 13 weeks. GI side effects were more common at the higher doses, mostly early.

    The science

    VENTURE TEAEs, 10 mg vs 15 mg vs placebo: any GI 71% / 83% / 37%; nausea 37% / 63% / 20%; vomiting 17% / 29% / 0; stopped for an AE 11% / 20% / 0 (Bays 2026).

    Sources
    • Bays et al. (VENTURE) (2026)

    Updated Nov 2026

  5. Day 43–546 · 17.5 mgClinical

    The top phase 3 dose

    You're at 17.5 mg, the highest phase 3 dose. In Viking's maintenance study, a group kept on 17.5 mg weekly reached about 22% average loss by week 33 and was still losing.

    The science

    Maintenance study Part 1 (180 adults with a BMI of 30 or more, no comorbidities; 21-week induction at 15 to 22.5 mg weekly, titrated every 2 weeks): week-21 loss about 16% to 19% vs about 0% on placebo; 98% reached 5%, 90% 10%, 65% 15% and 32% 20%. An exploratory group on 17.5 mg weekly through week 33 reached about 22% with no plateau (Viking, Oct-28-2026; topline, not yet a paper).

    Sources
    • Viking (Q3 2026 update) (2026)

    Updated Nov 2026

  6. Any dayRCT

    What VK2735 is built on

    A phase 1 trial, a 13-week phase 2 trial of the shot, a 13-week phase 2 trial of the tablet, and a maintenance study. Two phase 3 programs are running: VANQUISH for the shot since 2025 and SUNRISE for the tablet since late 2026. It is not approved anywhere.

    The science

    Phase 1 SAD/MAD in Australia (NCT05203237): half-life 170 to 250 hours after single shots, up to 7.8% loss from baseline after 28 days (Viking, Mar-28-2023). VENTURE (Bays 2026; NCT06068946, sponsor Viking, 20 US sites). VENTURE-Oral (NCT06828055): up to 12.2% at 13 weeks on daily tablets, GI events similar to placebo (Viking, Oct-28-2026). Phase 3: VANQUISH-1 (NCT07104500, ~4,500, 78 weeks), VANQUISH-2 (NCT07104383, with type 2 diabetes); SUNRISE-1 and -2 (tablet: 27.5, 35 or 55 mg daily, 68 weeks).

    Sources
    • Viking (phase 1 release) (2023)
    • Bays et al. (VENTURE) (2026)
    • Viking (Q3 2026 update) (2026)

    Updated Nov 2026

  7. With BPC-157Community

    Why people add BPC-157 to a GLP-1

    GI side effects come mostly early, and BPC-157, first studied as a stomach-protecting peptide, is added to ease them. Commonly reported: smoother first weeks. No trial has tested the pair.

    The science

    BPC-157's early research was on gastric protection in animal studies (Sikiric 2018 review). No trial has tested it alongside VK2735 or any GLP-1 drug; the pairing comes from community reports.

    Sources
    • Sikiric et al. (2018)

    Updated Nov 2026

After week 8

  1. Day 150+Clinical

    Holding the loss on fewer shots

    Viking is testing whether a shot every other week or once a month can hold the loss. In its first maintenance study, people kept 82% to 97% of their loss over 12 weeks on the less frequent shots, against 61% on placebo. Continue, space out or stop is a call for you and your clinician.

    The science

    After 21 weekly doses, groups moved to every-other-week dosing (83% to 97% of the loss retained at week 33) or monthly dosing (82% to 90%) vs 61% after switching from 17.5 mg weekly to placebo (each p < 0.01); GI events in the maintenance period were low (Viking, Oct-28-2026). Part 2, with daily tablet options, is running. Topline only.

    Sources
    • Viking (Q3 2026 update) (2026)

    Updated Nov 2026

Day 1 is the day you start it.

Phase 1 (Viking release, Mar-28-2023), phase 2 VENTURE RCT (Bays 2026, Obesity; NCT06068946), Viking updates Feb-11-2026 and Oct-28-2026, VANQUISH records on ClinicalTrials.gov. Investigational.

Moderate evidence

Mixing and a typical run.

Example numbers

Reconstitution example

Reconstitute a 10 mg vial of VK2735 with 2 mL of bacteriostatic water and a 2.5 mg dose is 50 units on a U-100 syringe, about 4 doses per vial.

Vial
10 mg
Water
2 mL
Amount
2.5 mg

Draw to50 units

0.5 mL insulin syringe · 50 units

Mix it in the Reconstitution LabOpen the calculator

Run notes

Cycle
Used continuously, once weekly, in its trials: 13 weeks in phase 2 and 78 weeks in phase 3. In Viking's maintenance study, people who switched after 21 weekly doses to a shot every other week or once a month kept most of their loss over the next 12 weeks; on placebo they kept about 61%.Community practice — opinions vary. Not a clinical recommendation.
Timing
Once weekly SubQ, same day each week, in its trials. VENTURE started at 2.5 mg (5 mg for its 15 mg group) and stepped up every 3 weeks to 5, 10 or 15 mg; phase 3 tests 7.5, 12.5 and 17.5 mg. The tablet is a daily dose in its own trials (27.5 to 55 mg in phase 3), not interchangeable mg for mg with the shot. These are trial schedules, not an approved regimen.
Route
SubQ injection
Stacks
BPC-157 (GI support)

Track it in the app

Safety.

Common side effects

  • Nausea
  • Constipation
  • Diarrhea
  • Vomiting
  • Acid reflux
  • Fatigue
  • Dry mouth

Interactions

No interaction studies have been published. GLP-1 drugs slow stomach emptying, which can change how oral medicines are absorbed. It is a GLP-1 drug itself, so it is not stacked with another one. With insulin or a sulfonylurea, discuss glucose monitoring with your clinician.

Safety notes

VK2735 has no label: it is still in trials. In the 13-week phase 2 VENTURE trial, GI side effects affected 51% to 83% across doses vs 37% on placebo, mostly mild or moderate, early, and fading over time; nausea was highest in the first week of the 15 mg group, the only one started at 5 mg instead of 2.5 mg. 9.1% stopped the drug for side effects (none on placebo), most often for nausea or vomiting. It is a GLP-1 drug, so the class warnings in GLP-1 labels (including pancreatitis, gallbladder disease and the rodent thyroid C-cell finding) are the ones to read. These are trial findings to review with your clinician.

Mixing charts by vial size.

Questions people ask.

What is VK2735?

A weekly GLP-1 and GIP dual agonist from Viking Therapeutics, the same two-receptor approach as tirzepatide, also being tested as a daily tablet. In its 13-week phase 2 trial, people lost about 9% to 15% of their body weight depending on the dose, with no sign of levelling off.

How is VK2735 dosed in research?

The research range for VK2735 is 2.5–17.5 mg, weekly, with a 2.5 mg starting dose. Studied in research — not a recommendation.

How long does VK2735 last?

The half-life of VK2735 is ~9 days (measured in people: 170–250 hours after single doses, Viking phase 1, 2023).

What do people report on VK2735?

Commonly reported on VK2735: in trials, nausea and other GI effects early on, fading as the dose holds. It is in phase 3 and not approved anywhere.

Is VK2735 safe?

The research basis for VK2735 is moderate: animal studies + some human data. Common side effects in the library: nausea, constipation, diarrhea, vomiting, acid reflux, fatigue and dry mouth.

What does VK2735 stack with?

Common stacks for VK2735: BPC-157 (GI support).

Track it in the app

Research.

The literature

Search the latest research

Reference.

Cadence

Weekly

Half-life

~9 days

~9 days (measured in people: 170–250 hours after single doses, Viking phase 1, 2023)

Research basis

●●● Moderate

Animal studies + some human data

PepVault for iPhone

Track VK2735 in PepVault

Log each dose, see how many doses are left in the vial, and keep your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo

Reviewed How we check the library